CRLF2 F232C

CI-VAR-00001094Explore in graph →NP_071431.2:p.Phe232CysNM_022148.4:c.695T>GClinVar 376003 CIViC 2285

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Adult B Acute Lymphoblastic Leukemia1
CRLF2 F232C	(prognostic)	Prognostic	D	Supports Poor Outcome	4	submitted	EID6094 In vitro expression experiments of CRLF2 F232C in murine BaF3 cells and human UT7 cells show that this mutation leads to constitutive dimerization and cytokine-independent signaling. This leads to tra… (full text at CIViC) PMID 20018760 · Yoda et al., 2010 · Open in CIViC	civic
B Lymphoblastic Leukemia/Lymphoma1
CRLF2 F232C	JAK Inhibitor I	Predictive	D	Supports Sensitivity Response	4	submitted	EID7210 The CRLF2 Phe232Cys somatic mutation was identified in 3/14 adult B-ALL specimens overexpressing CRLF2. Functional studies in BaF3 cells demonstrated constitutive dimerization, and retains ability to … (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.